- Amarin press release ( NASDAQ: AMRN ): Q2 Non-GAAP EPS of -$0.09 misses by $0.03 .
- Revenue of $94.4M (-38.9% Y/Y) beats by $6.19M .
- This decrease was driven by a decline in volume and net selling price due to the impact of an increase in generic competition in the U.S.
- Given the ongoing global impact of COVID-19, as well as the uncertainty resulting from the impact of generic IPE availability in the U.S. and challenges for most drugs seeking market access in Europe, Amarin will continue to suspend 2022 revenue guidance.
For further details see:
Amarin Non-GAAP EPS of -$0.09 misses by $0.03, revenue of $94.4M beats by $6.19M